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Summary 
In this perspective, we discuss developments in mass spectrometry-based proteomic 
technology in the last decade from the viewpoint of our laboratory. We also reflect on existing 
challenges and limitations, and explore the current and future role of quantitative proteomics in 
molecular systems biology, clinical research and personalized medicine. 
  
 2 
Introduction 
Proteins constitute a large part of the molecular machinery of the cell and are the major class of 
biomolecules targeted by drugs. Organized in functional modules and networks, they carry out 
cellular functions and determine phenotypes by means of coordinated activities of a multitude of 
molecular species1. Traditional biochemical methods for studying proteins have been highly 
biased towards a relatively small subset of proteins for which high quality, mainly antibody-
based assays have been available2. Over the past two decades, mass spectrometry (MS)-
based methods have emerged as the method of choice for the confident and near exhaustive 
identification and quantification of the proteins contained in a biological sample and have 
significantly contributed to unraveling cellular signaling networks, to elucidating the dynamics of 
protein-protein interactions in different cellular states, and to improved diagnosis and molecular 
understanding of disease mechanisms. Overall, MS-based proteomics can reveal the 
quantitative state of a proteome and thereby provides insights into the biochemical state of the 
respective cell or tissue. In the following paragraphs, we will discuss important concepts and 
developments in proteomic technology and explore the current and future role of quantitative 
proteomics in molecular systems biology as well as clinical research and personalized medicine. 
 
 
Evolution of MS-based quantitative proteomics 
MS-based proteomics can be broadly grouped into top-down proteomics where intact proteins 
are measured and bottom-up proteomics where peptides are measured as surrogates for the 
respective protein; in this commentary, we will focus on bottom-up proteomics. The typical 
bottom-up proteomics workflow starts with trypsin digestion of a protein sample into short 
peptides which are then separated by liquid chromatography either directly or after biochemical 
fractionation (Figure 1A)3. As peptides elute from the chromatography column, they are 
subjected to electrospray ionization4,5 and are directly sprayed into the mass spectrometer, 
where two levels of MS measurement take place in tandem3. At the first level, a mass analyzer 
measures the mass-to-charge ratio (m/z) of peptide molecular ions (MS1). At the second level, 
m/z values of fragment ions resulting from the fragmentation of specific peptide ions are 
detected (MS2). The specific fragment ion pattern of each peptide ion together with its m/z value 
enable confident identification of peptides present in the sample. Identified peptide sequences 
can then be mapped to proteins and the signal intensities of either peptides or fragment ions 
can be used to estimate relative abundance changes across samples. 
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Figure 1. Standard MS-based proteomics workflow and acquisition schemes. (A) Proteins can be 
extracted from various biological samples, such as bacterial or mammalian cell culture, tissues or bodily 
fluids. They are then enzymatically digested into peptides, which are then subjected to reverse-phase 
liquid chromatography, ionized with electrospray ionization and sprayed into the mass spectrometer. The 
time dimension in B and C is this chromatographic time. (B) Different acquisition schemes for tandem MS 
sample the proteome in distinct ways. While the most widely used untargeted (also referred to as shotgun 
or data-dependent acquisition, DDA) is relatively simple and applicable to any sample without requiring 
prior knowledge, resulting data can suffer from missing data points due to the stochastic sampling 
process. In contrast, targeted acquisition acquires peptide and fragment ion data in a highly consistent 
manner allowing accurate and sensitive quantification, but is limited to a relatively small, pre-defined set 
of peptides. Data-independent acquisition (DIA) acquires data of all detectable fragment ions in a sample 
in a systematic and consistent manner, but due to the relatively large peptide ion isolation windows (m/z 
dimension) the resulting data is more complex than for the other two acquisition schemes. (C) DIA data 
can be analyzed in different ways, either directly analyzing the multiplexed MS2 spectra or first extracting 
a subset of informative fragment ion signals (requires prior knowledge) and using these to derive 
quantitative data for specific peptides36,40. 
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To account for technical variability at various stages of sample handling and during the actual 
measurement, in the mid-90s, we and others started to develop strategies based on isotopic 
labeling6,7, including chemical isotopic labeling8, metabolic isotopic labeling9, and isobaric 
tagging10,11. Another important application of isotopic labeling in MS is the use of labeled spike-
in peptides or proteins of known concentration that enable the determination of absolute 
concentrations of proteins in a sample, for example, in terms of number of molecules per cell or 
nanograms per milliliter of blood12. While label-based approaches are still the gold-standard for 
quantification by MS-based proteomic methods13, the past years have seen label-free 
approaches becoming more popular thanks to simpler experimental design and sample 
preparation6,14. Among the developments enabling this transition are the advance of 
commercially available high resolution and fast scanning instruments, such as the introduction 
of the Orbitrap (2005)15 and continuous improvement of  time-of-flight mass spectrometers16, 
combined with improvements in software for aligning multiple MS runs17,18. Another more recent 
trend, starting in 200619, is label-free absolute quantification, where the absolute concentrations 
of all proteins measured in a sample are estimated based on summarized ion counts, which can 
then be converted into a meaningful unit by comparison to the total amount of protein that was 
injected into the mass spectrometer or by correlation to a set of spiked-in reference peptides of 
known concentration20-23. 
 
Regardless of whether label-based or label-free strategies are used, bottom-up proteomic 
methods have traditionally been divided into discovery proteomics and targeted proteomics 
(Figure 1B). Discovery proteomics (also known as shotgun proteomics and exemplified by data-
dependent acquisition, DDA) has its strength in identifying thousands of proteins per run. 
However, in complex samples, we have often been faced by limitations regarding repeatability 
of peptide identification and consistency of quantification24,25. Recent developments in 
chromatographic performance and MS hardware alleviate some of these concerns and allow 
high-quality quantitative measurements of near-complete proteomes, even in highly complex 
samples such as human cell lines and tissues26-29. 
 
About a decade ago, in order to overcome the limited scalability and reproducibility of discovery 
proteomics in studies aiming to quantify proteins in cohorts consisting of large numbers of 
samples, we and others started exploring the capabilities of targeted proteomics (exemplified by 
selected/multiple reaction monitoring, S/MRM30,31, and more recently parallel reaction 
monitoring, PRM32,33). Targeting methods provide consistent and accurate quantification, even 
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at low abundances and in complex mixtures. While targeted proteomics is typically limited to a 
few dozen predefined proteins per run, its sensitivity and highly quantitative capabilities make it 
well-suited for hypothesis-driven research and clinical studies where a smaller number of 
proteins, such as potential biomarkers, are to be measured in large numbers of patient 
samples34. 
 
Placed between these two well established techniques, a third type of mass spectrometric 
acquisition has gained remarkable momentum in the past five years: data-independent 
acquisition (DIA)35,36. In this method, multiplexed fragment ion spectra are acquired 
systematically using deterministic peptide ion isolation windows that collectively span the mass 
range in which most tryptic peptides are expected (Figure 1B). DIA was first described in the 
early 2000s37,38 and the following years have seen various further implementations and 
developments of the concept35,36. While these methods were of substantial conceptual interest 
and also led to a commercial implementation referred to as MSE 39, adoption of them in the field 
was somewhat limited due to the overwhelmingly complex data resulting from their application 
to high-complexity samples. In 2012, our lab described a new DIA-based method termed 
SWATH-MS, which uses a targeted paradigm for the analysis of DIA data40. The novel analysis 
strategy based on comprehensive spectral libraries41 and refined targeted scoring algorithms42, 
together with improved instrumentation and an optimized acquisition scheme, enabled us to 
efficiently deconvolute the highly multiplexed DIA data and use it to achieve highly consistent 
quantification of thousands of analytes (Figure 1C). Latest developments to improve DIA 
methods include: coupling with ion mobility43, new acquisition schemes44, as well as new data 
analysis modes and software tools45,46. Combining the analyte throughput of discovery 
proteomics with the accuracy and repeatability of targeted proteomic methods, DIA/SWATH-
type techniques have been applied successfully in a variety of studies and are becoming 
increasingly prevalent in the quantitative proteomics field, particularly in studies that require the 
consistent analysis of large sample cohorts23,47-50. 
 
Over the years, sensitivity and speed of mass spectrometers has improved at a rapid pace, 
however, obtaining robust, quantitative data over large numbers of samples remains one of the 
greatest challenges in proteomics, even for expert labs51. The most rigorous way to assess the 
capabilities and pitfalls of proteomic methods are inter-laboratory comparison studies. Such 
studies were conducted for discovery proteomics24,52 as well as targeted proteomics53. In a 
recent study using DIA/SWATH-type methods54,55, we found that over 4000 proteins from over 
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200 measurements of a human cell line can be independently identified and quantified across 
laboratories and instruments with coefficients of variation typically around 20%54. These results 
are encouraging because they show that quantitative proteomics is capable of delivering 
accurate, reproducible and comprehensive data at high throughput.  
 
In the following two sections, we briefly outline our view of the fields’ current and future role in 
molecular systems biology as well as in clinical research and applications. 
 
 
Quantitative proteomics in molecular systems biology and the study of cellular 
organization 
The comprehensive quantification of proteins, and their post-translational modification status 
across conditions, or over time in response to a stimulus or perturbation, is an important aspect 
of systems biological studies. Thanks to the technological advances described above, the 
quality of the resulting quantitative data matrices for large sample numbers has substantially 
improved, enabling us and others to conduct systems-oriented studies, not only in 
microorganisms, but also higher organisms, including mammals23,47,50,56,57. 
 
Proteins are not isolated molecules but three-dimensional objects acting in the context of other 
proteins, the modular and spatial organization of proteins can therefore be as important as their 
expression levels1,58. MS-based proteomic methods developed to query the organizational units 
of the proteome typically combine MS measurements with biochemical assays (Figure 2). The 
oldest of these methods, first described in 199959, is affinity purification coupled to MS to find 
interaction partners of a specific protein60-62. More recently, proteome fractionation using native 
separations has been applied to study protein complexes in a cell on a proteome-wide scale63-65. 
To determine subunit topologies of protein complexes and thereby obtain insights into the 
architecture of macromolecular assemblies, we and others have used approaches based on 
chemical cross-linking of protein residues66-68; adding a quantitative dimension enables probing 
of dynamic changes in protein complex composition and structure69,70. Furthermore, spatial 
resolution of the proteome within a cell can be added by combining proteomic techniques with 
enzymatic activities to label proximate or interacting proteins of a particular protein of interest71. 
Overall, these techniques highlight the power and flexibility of MS-based proteomics to not only 
produce a comprehensive and high-quality data matrix of protein abundances across a large 
number of samples, but also to obtain a dynamic, three-dimensional view of the proteome and 
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its modular and spatial organization, both of which are critical to fully understand complex 
biological systems.  
 
 
 
Figure 2. A selection of methods to explore the modular and spatial organization of the proteome.  
Two methods to study protein-protein interactions and complexes as they occur within a cell are affinity 
purification and protein correlation profiling. For both methods, cells are lysed under native conditions 
preserving protein-protein interactions. For affinity purification, a protein of interest is purified either via an 
affinity tag genetically added to the protein or with a specific antibody and subjected to MS analysis to 
identify proteins directly or indirectly binding to the protein of interest60. For protein correlation profiling, a 
cell lysate is fractionated e.g. by size-exclusion chromatography and after MS analysis of all the resulting 
fractions, correlation analysis is performed to find co-elution of proteins indicative of them having been 
part of the same protein complex63-65. Chemical cross-linking can be used to gain insights into the 
topology of a protein complex 66-68. After digestion of cross-linked proteins, cross-linked peptides can be 
identified by MS and provide information on which parts of which proteins are in close proximity within the 
protein complex. Another emerging method is proximity labeling (also called BioID) using a ubiquitous 
biotin-ligase fused to a protein of interest to biotinylate all proteins in its proximity71. Biotinylated proteins 
can then be isolated and identified by MS. The BioID method captures not only stable protein complexes 
but also transient interactions between proteins that could not be captured by the other methods 
mentioned here. 
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Quantitative proteomics in molecular medicine 
One of the major challenges in clinical studies is the requirement for large patient cohorts to 
cope with biological and experimental variability of clinical samples. In contrast to genomics, 
proteomic analyses of cohorts consisting of hundreds of samples are still prohibitively time-
consuming and expensive, especially if large numbers of proteins are to be consistently 
quantified across the cohort. Two remarkable studies from 2016 used discovery proteomics to 
quantify several thousand proteins across over a hundred patient samples each; both efforts 
required several months of instrument time72,73. To conduct studies at larger scale, proteomic 
techniques that allow higher throughput, while maintaining robustness, repeatability and 
sensitivity are therefore essential. DIA/SWATH-type approaches emerge as a promising 
alternative for the quantitative proteomic analysis of clinical samples and first studies applied 
them successfully to quantify large numbers of proteins across hundreds of human patient 
samples74. 
 
The datasets generated from such studies can be used to discover cellular mechanisms and 
processes that are affected in the disease under study. Alternatively, quantitative proteomic 
techniques can be used to profile potential protein biomarkers in patient tissue, blood or urine to 
 
Figure 3. Quantitative proteomics in molecular medicine. Applications of quantitative proteomics in 
personalized medicine are typically based on biomarkers that reflect disease risk or disease status. 
Biomarkers are screened across individuals or patient cohorts. Longitudinal profiling of individuals allows 
monitoring of the molecular profile of a person over long time frames; and more meaningful clinical 
information can be obtained by comparing each measurement with previous time points of the same 
person than by comparing a single measurement with the population average. This personalized 
approach to molecular medicine is expected to achieve early and highly sensitive detection of disease 
risk and is therefore most effective in preventing disease. 
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inform disease risk, diagnosis, prognosis, and treatment stratification (Figure 3). Biomarkers 
also play a crucial role in the emerging field of personalized medicine, where recurrent 
molecular measurements of specific protein and metabolite levels are used to evaluate an 
individual’s health status and to prevent development of disease in a timely manner by dietary, 
exercise or drug-based interventions (Figure 3)75. While protein biomarkers have traditionally 
been measured with immunoassays, targeted proteomic techniques have a number of 
advantages, including faster assay development, multiplexing capabilities and analytical 
specificity, and are therefore the method of choice to test panels of candidate biomarkers before 
they enter clinical validation studies76-78.  
 
 
Conclusion 
Over the past two decades, we have witnessed rapid developments in mass spectrometric 
instrumentation as well as acquisition methods and analysis strategies. Furthermore, 
quantitative proteomics has contributed enormously to biological and clinically oriented 
research. However, current instrument operation as well as data acquisition and analysis still  
require highly specialized expertise. Many facilities, including ours, are therefore working 
towards the development of more robust MS-based methods and automated analysis pipelines 
to make quantitative proteomics available, not just to expert labs, but also to general molecular 
biology laboratories in academia, hospitals and industry. 
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